US Dollar vs MXN

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

REGN Regeneron Pharmaceuticals Inc

985.02

4.45 (0.45%)

24 May 2024 - Cerrado

Retrasado por 15 minutos

Biotech Shares Soar Premarket On Sale Of R&D Assets

A Massachusetts-based biotech company is stealing the show so far during Tuesday’s premarket hours after it was announced that the company has agreed to sell its pipeline of...

To read the full story on AllPennyStocks.com, click here.

Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Haga Click aquí para más Gráficas Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfica de Acción Histórica
De May 2023 a May 2024

Haga Click aquí para más Gráficas Regeneron Pharmaceuticals.

Noticias sobre Regeneron Pharmaceuticals Inc REGN

Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
Jueves 23 de Mayo 2024 (3 días hace) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 22 de Mayo 2024 (4 días hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Martes 21 de Mayo 2024 (5 días hace) • Edgar (US Regulatory)

Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
Lunes 20 de Mayo 2024 (6 días hace) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Viernes 17 de Mayo 2024 (1 semana hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Viernes 17 de Mayo 2024 (1 semana hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Viernes 17 de Mayo 2024 (1 semana hace) • Edgar (US Regulatory)

More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
Viernes 17 de Mayo 2024 (1 semana hace) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 15 de Mayo 2024 (2 semanas hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Martes 14 de Mayo 2024 (2 semanas hace) • Edgar (US Regulatory)

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
Lunes 13 de Mayo 2024 (2 semanas hace) • GlobeNewswire Inc.

Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
Miércoles 8 de Mayo 2024 (3 semanas hace) • GlobeNewswire Inc.

Más de Regeneron Pharmaceuticals Inc Artículos de Noticias

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones